Video Experimental Relacionado

Updated: Feb 26, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Objetivos biológicos emergentes en el asma tipo 2 y no tipo 2

Andrea E Davis^1,2, Sarah Rhoads², Michael E Wechsler²

¹Division of Pulmonary, Allergy and Critical Care Medicine, the Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora.

Current opinion in pulmonary medicine

|February 24, 2026

Abstracto

Purpose Of Review:

Severe asthma continues to be a significant cause of global morbidity and mortality despite the dramatic change in landscape of asthma management dramatically over the last two decades, However, there are a variety of novel therapeutic agents under investigation whose goals are to enable patients with severe asthma to achieve remission.

Recent Findings:

New strategies in drug development include an ultra-long-acting mechanism with reduced administration frequency, biologics used in combinations, oral therapies and novel therapeutic targets. These targets include bruton tyrosine kinase, OX-40 ligand, janus kinase, CC-chemokine receptor4 (CCR4), and GATA-3, among others reviewed here.

Summary:

Many patients have benefited tremendously from the currently available asthma biologics in achieving better symptoms control, improved quality of life, and reduced cumulative dose of systemic steroids. Despite this, most patients are unable to achieve remission, potentially related to shortcomings of these therapies in addressing asthma's heterogeneous pathophysiology. As such, a variety of novel therapeutic mechanisms and targets are being investigated and are discussed in this review.

Palabras clave:

asma biológico remisión

Más Videos Relacionados

Murine Model of Allergen Induced Asthma

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

Videos de Conceptos Relacionados

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...